Media & Press
April 1, 2019
A once abandoned drug compound shows an ability to rebuild organs damaged by illness and injury.
March 30, 2019
Novo Biosciences Inc., has achieved several major milestones in its mission of bringing its breakthrough drug candidate, trodusquemine (aka MSI-1436), to market as a potential regenerative medicine treatment for heart disease and Duchenne muscular dystrophy.
September 7, 2017
Novo Biosciences Inc. has announced that it has received a two-year, $1.5 million Small Business Innovation Research (SBIR) grant from the National Institutes of Health (NIH) for the development of MSI-1436 as a potential regenerative medicine therapy for the treatment of patients who have suffered an acute heart attack.
March 16, 2017
While stem cell and tissue engineering approaches may ultimately deliver on their clinical promise, small molecules that control innate regeneration mechanisms offer a less complex and more economical path to realizing regenerative medicine’s transformative potential.
March 14, 2017
US researchers claim to have identified a groundbreaking drug that could restore heart muscle function following a heart attack. A new study describes how MSI-1436, a naturally occurring compound, regenerates heart muscle tissue in zebrafish and mice. The animals are separated by 450 million years of evolution, raising hopes that the drug could help heal human hearts too.
August 23, 2016
A federal patent has been awarded to scientists at Novo Biosciences, a step that will allow research to proceed on a molecule that shows promise in helping heart tissue regenerate after a heart attack.